EXSCIENTIA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.3 USD | +7.29% |
|
+13.01% | -17.32% |
| May. 21 | Sector Update: Health Care Stocks Edge Higher Tuesday Afternoon | MT |
| May. 21 | Exscientia to Reduce Up to 25% Workforce by Year End | MT |
| Sales 2024 * | 57.84M 73.69M | Sales 2025 * | 49.08M 62.53M | Capitalization | 526M 671M |
|---|---|---|---|---|---|
| Net income 2024 * | -116M -148M | Net income 2025 * | -120M -153M | EV / Sales 2024 * | 5.5 x |
| Net cash position 2024 * | 209M 266M | Net cash position 2025 * | 403M 514M | EV / Sales 2025 * | 2.51 x |
| P/E ratio 2024 * |
-4.95
x | P/E ratio 2025 * |
-5.09
x | Employees | 483 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 58.7% |
More Fundamentals
* Assessed data
More news
Latest transcript on Exscientia plc
More recommendations
More press releases
More news
| 1 day | +7.29% | ||
| 1 week | +13.01% | ||
| 1 month | +3.11% | ||
| 3 months | -18.71% | ||
| 6 months | -14.10% | ||
| Current year | -17.32% |
1 week
4.47
5.47
1 month
4.475.47
Current year
3.867.91
1 year
3.869.12
3 years
3.8630.38
5 years
3.8630.38
10 years
3.8630.38
| Managers | Title | Age | Since |
|---|---|---|---|
David Hallett
CEO | Chief Executive Officer | 54 | 20-01-20 |
Ben Taylor
DFI | Director of Finance/CFO | 46 | 20-11-17 |
| Chief Tech/Sci/R&D Officer | - | 22-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mario Polywka
BRD | Director/Board Member | 61 | 17-09-27 |
Elizabeth Crain
CHM | Chairman | 59 | 21-02-08 |
Ben Taylor
DFI | Director of Finance/CFO | 46 | 20-11-17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 5.3 | +7.29% | 726,700 |
| 24-05-30 | 4.94 | +5.78% | 410,674 |
| 24-05-29 | 4.67 | -1.89% | 482,052 |
| 24-05-28 | 4.76 | +1.49% | 413,236 |
| 24-05-24 | 4.69 | -0.85% | 382,620 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Exscientia PLC is a United Kingdom-based artificial intelligence (AI)-driven precision medicine company. It is focused on discovering, designing, and developing the possible drugs. It has developed the functional precision oncology platform to guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Its internal pipeline is focused on leveraging its precision medicine platform in oncology, while its partnered pipeline broadens its approach to other therapeutic areas. Its patient-first AI platform includes Patient-first AI, Precision Target, Precision Design, Precision Experiment, and Precision Medicine. Its Precision Target combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. The Companyâs advanced biophysical and x-ray techniques provide the ideal experimental underpinnings for AI-design.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
4.165
GBP
Average target price
6.595
GBP
Spread / Average Target
+58.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.32% | 670M | |
| +43.36% | 54.63B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- EXAI Stock
